Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

21 Feb 2020

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Breast Cancer Treatment Studies
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32245699
DOI: 10.1016/j.annonc.2020.02.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancerPMID 32245699Read ↗

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in <i>BRCA1/2</i> -mutant metastatic breast cancerSemantic proximity Read ↗

Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?Semantic proximity Read ↗

PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments.Semantic proximity Read ↗

A meta-analysis of clinical cases of reversion mutations in <i>BRCA</i> genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistanceSemantic proximity Read ↗

‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancerSemantic proximity Read ↗

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.Semantic proximity Read ↗

Non-genetic mechanisms of therapeutic resistance in cancerSemantic proximity Read ↗

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.Semantic proximity Read ↗

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.Semantic proximity Read ↗

Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatmentSemantic proximity Read ↗

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.Semantic proximity Read ↗

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.